Overview

Prophylactic Ivermectin in COVID-19 Contacts

Status:
Completed

Trial end date:
2020-07-27

Target enrollment:

Participant gender:

Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Zagazig University

Treatments:

Ivermectin